[Osteoporosis in men].
Ringe
J D
JD
Medizinische Klinik IV, Schwerpunkt Rheumatologie/Osteologie, Klinikum Leverkusen. ringe@klinikum-lev.de
D019386:Alendronate / Q000627:therapeutic use; D000728:Androgens / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003937:Diagnosis, Differential; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D007006:Hypogonadism / Q000150:complications / Q000188:drug therapy; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D011322:Primary Prevention; D000068296:Risedronic Acid; D012307:Risk Factors
D000728:Androgens; D002121:Calcium Channel Blockers; D006887:Hydroxycholecalciferols; D000068296:Risedronic Acid; D012968:Etidronic Acid; C008088:alfacalcidol; D019386:Alendronate
Osteoporose des Mannes.